Login to Your Account

New data underscore benefits of idebenone in DMD as Biomarin pulls drisapersen MAA

By Cormac Sheridan
Staff Writer

Wednesday, June 1, 2016

DUBLIN – Even as Biomarin Pharmaceutical Inc.'s dwindling hopes for its exon-skipping pipeline in DMD turned to ash this week, with the withdrawal of its MAA for drisapersen from the EMA, there was also some positive news for DMD patients and their families.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription